Calliditas Therapeutics Q2 EPS $(0.16) Up From $(0.74) YoY, Sales $25.61M Up From $6.51M YoY, Cash Balance $82.33
Portfolio Pulse from Benzinga Newsdesk
Calliditas Therapeutics reported Q2 earnings with losses of $(0.16) per share, a 77.88% increase YoY. Sales were reported at $25.61M, a 293.04% increase YoY. The company's cash balance stands at $82.33M.
August 17, 2023 | 7:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Calliditas Therapeutics reported improved Q2 earnings with a significant increase in sales and reduced losses per share YoY.
Calliditas Therapeutics reported a significant improvement in its Q2 earnings, with a 77.88% increase in EPS and a 293.04% increase in sales YoY. This positive financial performance could potentially lead to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100